Compounded medications can fill important treatment needs, but they do not go through the same premarket approval process as FDA-approved drugs. The SAFE Drugs Act would strengthen oversight by improving serious adverse-event reporting, increasing visibility into interstate distribution, and helping patients and providers identify compounded medications through clearer labeling.

This bill addresses gaps in the oversight of compounded medications. Compounding allows pharmacies and other facilities to prepare medications for patients who may need a specific dosage, strength, or form that is not commercially available. While this can provide an important alternative, compounded drugs do not go through the same premarket approval process as FDA-approved medications. This makes clear rules and reporting requirements important for understanding how these products are made and used.

The bill also focuses on adverse event reporting. Requiring certain compounders to report serious problems associated with their products would give federal regulators more information about potential risks. This could make it easier to recognize patterns involving a particular medication or facility and determine when further action may be necessary.

Finally, the legislation is significant because it focuses on transparency for patients and healthcare providers. Additional labeling requirements could make it easier to distinguish compounded medications from FDA-approved products. This information can help patients and providers better understand what they are receiving and make more informed decisions about treatment.

The objective of the Safe Drugs Act is to strengthen oversight and transparency around compounded medications, helping regulators better understand potential risks and helping patients and providers make informed decisions. Please urge members of the House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions (HELP) Committee to support the bill.